MariTide
Also known as: maridebart cafraglutide, AMG 133
Status
In trials. Not approved. In phase 3 development with Amgen.
What it is
An antibody-peptide conjugate dosed monthly or less often, taking the opposite approach to GIP.
What published research measured
Mechanistically the odd one out: it activates the GLP-1 receptor while blocking the GIP receptor, the reverse of tirzepatide, which agonises both. That both strategies produce weight loss is one of the unresolved questions in the field. Its structure — GLP-1 peptides conjugated to an anti-GIP-receptor antibody — gives it a long enough half-life for monthly or less frequent dosing. The MARITIME phase 3 program is recruiting.
Source
Jastreboff AM et al. 2025 — Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial · Bailey CJ et al. 2025 — Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities · Véniant MM et al. 2024 — A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinica…
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.